We're working on something new at CrunchBase. Edits have been disabled for a few days, but you can still contact us for urgent changes.
Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events


Post IPO Valuation

General Information

DescriptionAmerican biotechnology company


Celgene Corporation
86 Morris Avenue
Summit, NJ, 07901
Celgene International
Switzerland – Boudry
Route de Perreux 1 Boudry
Boudry, CH-2017, CHE


CEO, Celgene Cellular Therapeutics (CCT) and EVP, Chief Operations Officer
Board of Directors
Board of Directors/Chairman of the Nominating and Governance Committee, and Member of the Executive and Compensation Committees
Board of Directors/Chairman of the Compensation Committee and Member of the Nominating Committee
Board of Directors/Member of the Audit Committee
Board of Directors/Chairman of the Audit Committee and Member of the Compensation Committee
Board of Directors and Audit Committee
Board of Directors
Show All People


Avila Therapeutics, 1/2012 $350M
Abraxis BioScience, 6/2010 $2.9B
Gloucester Pharmaceuticals, 12/2009 $640M
Pharmion, 11/2007 $2.9B




Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options.

There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma.

In addition, several compounds are being evaluated as therapies for serious inflammatory diseases such as psoriasis and psoriatic arthritis.

Recent Milestones



Celgene screenshot
Above: Celgene Screenshot -- #1
Uploaded: 4/15/14

Stock Price


  1. Celgene to acquire Avila Therapeutics (reuters.com) [edit]
  2. Celgene strikes $2.9B deal to acquire Abraxis (fiercebiotech.com) [edit]
  3. Gloucester Pharma selling for $640M to Celgene (masshightech.com) [edit]
  4. Celgene to Acquire Pharmion For $2.9 Billion in Cash, Stock (online.wsj.com) [edit]
  5. Epizyme stock up on $10M investment from partner Celgene (bizjournals.com) [edit]
  6. Atara Biotherapeutics Holds $13.5M Second Close of Series B FINANCING (finsmes.com) [edit]
  7. Atara Biotherapeutics Secures $38.5M in Series B Financing (finsmes.com) [edit]
  8. Sutro Biopharma Secures $26M in Series D Financing (finsmes.com) [edit]
  9. Acetylon Scores $100M Investment from Celgene for Cancer Research (bostinno.streetwise.co) [edit]
  10. Tengion closes on $33.6M to continue regenerative medicine R&D (wraltechwire.com) [edit]
  11. VentiRx Secures $35M from Celgene; VCs Get Possible Path to Liquidity (pevc.dowjones.com) [edit]
  12. Acetylon Announces $15 Million Strategic Equity Investment by Celgene Corporation (finance.yahoo.com) [edit]
  13. Acceleron Pharma Raises $30M in Funding (finsmes.com) [edit]
  14. Agios Pharmaceuticals Raises $78M in Series C Financing (finsmes.com) [edit]
  15. FerroKin rounds up $12M for iron overload treatment Read more: FerroKin rounds up $12M for iron overload treatment - FierceBiotech http://www.fiercebiotech.com/story/ferrokin-rounds-12m-iron-overload-treatment/2010-06-18?utm_medium=rss&utm_source=rss#ixz (fiercebiotech.com) [edit]
  16. Celgene invests $100M, gains option to buy Acetylon (smartbrief.com) [edit]
    Celgene forges $35M cancer, fibrosis discovery pact with PharmAkea (fiercebiotech.com) [edit]
Edit This Page
Last Edited 4/16/14

Revision History RSS Picture


Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API


Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy